Clinical Trial Update: A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravenous ibandronate (Bondronat) for malignant and painful bone disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Bone Metastasis

Drugs mentioned

• Bondronat (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pain, Bone Neoplasm | Phase 3 | Status: TERMINATED